Literature DB >> 7083451

A radioimmunoassay for VP16-213 in plasma.

G W Aherne, V Marks.   

Abstract

A radioimmunoassay for the semi-synthetic podophyllotoxin VP16-213 has been developed which is suitable for pharmacokinetic studies of the drug. A high titre antiserum was produced in a sheep in response to a VP16-213-BSA conjugate prepared using sodium periodate. Podophyllotoxin does not cross-react with the antiserum and VM26 cross-reacts to only a small extent (less than 0.6%). In the absence of a high specific activity tritium label, a radioiodinated histamine ligand was produced which was only partially displaced from antibody by native drug. VP16-213 can be measured in plasma without prior drug extraction with a theoretical limit of detection of 5-10 micrograms/l. VP16-213 cis (picro) hydroxy acid is recognised by the antiserum to a greater extent than the drug itself. Thus, in order to eliminate any interference from the trans hydroxy acid metabolite chloroform extraction of plasma samples was carried out.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7083451     DOI: 10.1007/BF00254532

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  8 in total

1.  ANTIBODIES SPECIFIC FOR RIBONUCLEOSIDES AND RIBONUCLEOTIDES AND THEIR REACTION WITH DNA.

Authors:  B F ERLANGER; S M BEISER
Journal:  Proc Natl Acad Sci U S A       Date:  1964-07       Impact factor: 11.205

2.  Digoxin-specific antibodies.

Authors:  V P Butler; J P Chen
Journal:  Proc Natl Acad Sci U S A       Date:  1967-01       Impact factor: 11.205

3.  Radioimmunoassay and saturation analysis. Pharmacology.

Authors:  V Marks; B A Morris; J D Teale
Journal:  Br Med Bull       Date:  1974-01       Impact factor: 4.291

Review 4.  The practical benefits of pharmacokinetics in the use of antineoplastic agents.

Authors:  C Erlichman; R C Donehower; B A Chabner
Journal:  Cancer Chemother Pharmacol       Date:  1980       Impact factor: 3.333

5.  Analysis of the anticancer drugs VP 16-213 and VM 26 and their metabolites by high-performance liquid chromatography.

Authors:  R J Strife; I Jardine; M Colvin
Journal:  J Chromatogr       Date:  1980-05-09

6.  High-performance liquid chromatography determination of 4'-demethyl-epipodophyllotoxin-9-(4,6-O-ethylidene beta-D-glucopyranoside) (VP 16-213) in human plasma.

Authors:  P Farina; G Marzillo; M D'Incalci
Journal:  J Chromatogr       Date:  1981-01-02

7.  Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3a,6a-diphrenylglycoluril.

Authors:  P J Fraker; J C Speck
Journal:  Biochem Biophys Res Commun       Date:  1978-02-28       Impact factor: 3.575

8.  Development and application of a radioimmunoassay for methotrexate.

Authors:  G W Aherne; E M Piall; V Marks
Journal:  Br J Cancer       Date:  1977-11       Impact factor: 7.640

  8 in total
  3 in total

Review 1.  Etoposide and teniposide. Bioanalysis, metabolism and clinical pharmacokinetics.

Authors:  J J Holthuis
Journal:  Pharm Weekbl Sci       Date:  1988-06-17

2.  A highly sensitive enzyme-linked immunosorbent assay for etoposide using beta-D-galactosidase as a label.

Authors:  T Saita; K Fujiwara; T Kitagawa; M Mori; K Takata
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

Review 3.  The clinical pharmacology of etoposide and teniposide.

Authors:  P I Clark; M L Slevin
Journal:  Clin Pharmacokinet       Date:  1987-04       Impact factor: 6.447

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.